Does isoniazid chemoprophylaxis increase the frequency of hepatotoxicity in patients receiving anti-TNF-alpha agent with a disease-modifying antirheumatic drug?

Creative Commons License

ÜSKÜDAR CANSU D., Guncan S., Bilge N. S. Y., KAŞİFOĞLU T., KORKMAZ C.

EUROPEAN JOURNAL OF RHEUMATOLOGY, vol.1, no.2, pp.62-66, 2014 (ESCI) identifier identifier

  • Publication Type: Article / Article
  • Volume: 1 Issue: 2
  • Publication Date: 2014
  • Doi Number: 10.5152/eurjrheumatol.2014.019
  • Journal Name: EUROPEAN JOURNAL OF RHEUMATOLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.62-66
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

Objective: The aim of this study is to determine the incidence of isoniazid (INH)-related hepatotoxicity in patients with rheumatologic diseases receiving tumor necrosis factor-alpha (TNF-alpha) antagonists along with a disease-modifying antirheumatic drug (DMARD).